<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11849631
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     02
    </month>
    <day>
     18
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     03
    </month>
    <day>
     15
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0015-0282
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       77
      </volume>
      <issue>
       2 Suppl 2
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Feb
       </month>
      </pubdate>
     </journalissue>
     <title>
      Fertility and sterility
     </title>
     <isoabbreviation>
      Fertil. Steril.
     </isoabbreviation>
    </journal>
    <articletitle>
     Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.
    </articletitle>
    <pagination>
     <medlinepgn>
      S13-8
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To present efficacy and cycle control data pooled from three pivotal studies of the contraceptive patch (Ortho Evra/Evra).
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Three multicenter, open-label, contraceptive studies that included up to 13 treatment cycles.Setting: 183 centers.
     </abstracttext>
     <abstracttext label="PATIENT(S)" nlmcategory="METHODS">
      3,319 women.Intervention(s): Three consecutive 7-day patches (21 days) with 1 patch-free week per cycle.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURE(S)" nlmcategory="METHODS">
      Contraceptive efficacy and cycle control.
     </abstracttext>
     <abstracttext label="RESULT(S)" nlmcategory="RESULTS">
      Overall and method failure life-table estimates of contraceptive failure through 13 cycles were 0.8% (95% CI, 0.3%-1.3%) and 0.6% (95% CI, 0.2%-0.9%), respectively. Corresponding Pearl indices were 0.88 (95% CI, 0.44-1.33) and 0.7 (95% CI, 0.31-1.10). Contraceptive failure among women with a body weight &lt; 90 kg (&lt;198 lb) was low and uniformly distributed across the weight range. A subgroup of women with body weight &gt; or = 90 kg (&gt; or = 198 lb) may have increased risk of pregnancy. The incidence of breakthrough bleeding was low and decreased over time.
     </abstracttext>
     <abstracttext label="CONCLUSION(S)" nlmcategory="CONCLUSIONS">
      In contraceptive patch users, the overall annual probability of pregnancy was 0.8% and the method failure probability was 0.6%. The efficacy of the patch was high and similar across age and racial groups. Among women &lt; 90 kg (&lt;198 lb), contraceptive failure was low and uniformly distributed across the range of body weights. In women &gt; or = 90 kg (&gt; or = 198 lb), contraceptive failures may be increased. Efficacy and cycle control have been shown to be comparable to an established oral contraceptive.
     </abstracttext>
    </abstract>
    <affiliation>
     Emory University School of Medicine, Atlanta, Georgia, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Zieman
      </lastname>
      <forename>
       Miriam
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Guillebaud
      </lastname>
      <forename>
       John
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Weisberg
      </lastname>
      <forename>
       Edith
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Shangold
      </lastname>
      <forename>
       Gary A
      </forename>
      <initials>
       GA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fisher
      </lastname>
      <forename>
       Alan C
      </forename>
      <initials>
       AC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Creasy
      </lastname>
      <forename>
       George W
      </forename>
      <initials>
       GW
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Fertil Steril
    </medlineta>
    <nlmuniqueid>
     0372772
    </nlmuniqueid>
    <issnlinking>
     0015-0282
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Contraceptives, Oral, Combined
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Oximes
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      norelgestromin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      434-03-7
     </registrynumber>
     <nameofsubstance>
      Ethisterone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      57-63-6
     </registrynumber>
     <nameofsubstance>
      Ethinyl Estradiol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      6533-00-2
     </registrynumber>
     <nameofsubstance>
      Norgestrel
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Cutaneous
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Age Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Body Weight
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Contraceptives, Oral, Combined
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      standards
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Drug Delivery Systems
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ethinyl Estradiol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      standards
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ethisterone
     </descriptorname>
     <qualifiername majortopicyn="N">
      analogs &amp; derivatives
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Menstrual Cycle
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Norgestrel
     </descriptorname>
     <qualifiername majortopicyn="N">
      analogs &amp; derivatives
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Oximes
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Proportional Hazards Models
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      2
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      3
     </month>
     <day>
      16
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      2
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11849631
    </articleid>
    <articleid idtype="pii">
     S0015028201032757
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

